Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease (Q33914374)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Crohn's disease

0 references

ulcerative colitis

1 reference

based on heuristic

inferred from title

Alexander Markham

2

object named as

A Markham

0 references

author name string

D Clemett

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Markham

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

1 April 2000

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

59

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

929-956

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

21 January 2018

Mechanism of action of 5-aminosalicylic acid and its derivatives

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

21 January 2018

Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

21 January 2018

Mesalazine-associated interstitial nephritis

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

21 January 2018

Renal dysfunction and the treatment of inflammatory bowel disease (IBD): a case for monitoring

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

21 January 2018

New developments in the pharmacotherapy of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

21 January 2018

Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

21 January 2018

Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mesalamine capsules enhance the quality of life for patients with ulcerative colitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiology of inflammatory bowel disease: an update

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second trial of mesalamine therapy in the treatment of active Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic interstitial nephritis and mesalazine: 3 new cases?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Test of an instrument to measure function-related quality of life in patients with ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delivery and fate of oral mesalamine microgranules within the human small intestine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal and urologic complications of inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aberrant esophageal HLA-DR expression in a high percentage of patients with Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pentasa in lieu of sulfasalazine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of Crohn's disease in adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Release of 5‐ASA from Pentasa in patients with Crohn's disease of the small intestine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantification of distinct molecular species of platelet activating factor in ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacology in gastroenterology: development of new forms of treatment of inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Exanthema in 2 patients with ulcerative colitis treated with Pentasa]

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Side-effects of salazopyrin on male fertility

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mesalazine induced exacerbation of ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New therapeutic agents in the treatment of inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Release of platelet-activating factor (PAF) from human colon mucosa and its inhibition by 5-aminosalicylic acid

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of sulphasalazine-induced male infertility

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Pregnancy outcome in inflammatory bowel diseases]

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Class II antigen (HLA-DR) expression by intestinal epithelial cells in inflammatory diseases of colon

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease]

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Excessive production of reactive oxygen metabolites by inflamed colon: Analysis by chemiluminescence probe

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictability of the postoperative course of Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dissolution profiles of mesalazine formulations in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Aminosalycylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet-activating factor--a possible mediator in the pathogenesis of ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the treatment of ulcerative colitis in remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus andper os slow-release formulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Iatrogenic diffuse interstitial pneumonia linked to 5-aminosalicylate]

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salicylates for ulcerative colitis--their mode of action

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An experiment to determine the active therapeutic moiety of sulphasalazine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Cooperative Crohn's Disease Study: adverse reactions to study drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of Arachidonic Acid Metabolism by Olsalazine and Other Aminosalicylates in Leukocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of major histocompatibility complex class II antigens on human colonic epithelium by interferon-gamma, tumor necrosis factor-alpha, and interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of salazosulphapyridine and 5-aminosalicylic acid on seminal qualities and male sex hormones

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New salicylates as maintenance treatment in ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A practical guide to the management of distal ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of HLA-DR antigen expression on human colonic epithelium by tumor necrosis factor-alpha and interferon-gamma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The oxygen-centered radicals scavenging activity of sulfasalazine and its metabolites. A direct protection of the bowel

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea

1 reference

https://pubmed.ncbi.nlm.nih.gov/10804042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200059040-00016

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33914374&oldid=2195985175"